Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells.
10.4174/astr.2014.87.4.167
- Author:
Won Ho KIL
1
;
Sang Min KIM
;
Jeong Eon LEE
;
Kyoung Sik PARK
;
Seok Jin NAM
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. gilbak73@gmail.com
- Publication Type:Original Article
- Keywords:
Triple negative breast neoplasms;
Silibinin;
Xenograft
- MeSH:
Administration, Oral;
Animals;
Blotting, Western;
Breast Neoplasms*;
Female;
Gene Expression;
Heterografts*;
Humans;
Mice;
Phosphorylation;
Real-Time Polymerase Chain Reaction;
Receptor, Epidermal Growth Factor;
Triple Negative Breast Neoplasms;
Tumor Burden;
Vascular Endothelial Growth Factor A
- From:Annals of Surgical Treatment and Research
2014;87(4):167-173
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study is to know whether silibinin has an anticancer effect on triple negative breast cancer xenograft model using MDA-MB-468 cells. METHODS: To establish the xenograft model, we injected the MDA-MB-468 cells into female Balb/c-nude mice. After establishing a xenograft model, oral silibinin was administered to the tested mice in the way of 200 mg/kg for 45 days. The difference of mean tumor volume between silibinin fed mice and control mice was analyzed. The epidermal growth factor receptor (EGFR) phosphorylation in MDA-MB-468 cells was analyzed by Western blotting. The expression of VEGF, COX-2, and MMP-9 genes in tumor tissue was analyzed by real-time polymerase chain reaction (PCR). RESULTS: In the xenograft model using MDA-MB-468 cells, we found that oral administration of silibinin significantly suppressed the tumor volume (silibinin treated mice vs. control mice; 230.3 +/- 61.6 mm3 vs. 435.7 +/- 93.5 mm3, P < 0.001). The phosphorylation of EGFR in MDA-MB-468 cells was inhibited by treatment with 50 microg/mL of silibinin. In real time-PCR analysis of tumor tissue obtained from sacrificed mice, the gene expression of MMP-9, VEGF, and COX-2 was 51.8%-80% smaller in silibinin group than that of control group and we can also verify the similar result using Western blotting analysis. CONCLUSION: We verified that silibinin had anticancer effect on xenograft model of MDA-MB-468 cells in the way of preventing the phosphorylation of EGFR and eventually suppressed the production of COX-2, VEGF, and MMP-9 expression. Finally, the tumor volume of xenograft models was decreased after administration of Silibinin.
